The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
IGA score for patients with melasma or post-acne post-inflammatory hyperpigmentation (PIHP)
Timeframe: from baseline to Day84
modified Melasma Area Severity Index (mMASI) for patients with melasma
Timeframe: from baseline to Day 84
Post-Acne Hyper Pigmentation Index (PAHPI)
Timeframe: from baseline to Day 84
solar lentigo pigmentation scale
Timeframe: from baseline to Day84